Related Experiment Video

Updated: Aug 12, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.5K

Left atrial appendage closure for stroke prevention in atrial fibrillation: current status and perspectives

Ulf Landmesser1,2,3,4, Carsten Skurk1,4, Apostolos Tzikas5

  • 1Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite (DHZC), Hindenburgdamm 30, 12203 Berlin, Germany.

European Heart Journal
|July 19, 2024
PubMed

Insights

Left atrial appendage closure (LAAC) offers an alternative to oral anticoagulation for reducing stroke risk in atrial fibrillation (AF) patients. Ongoing trials and surgical approaches are expanding its role and safety profile.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Medical Devices

Background:

  • Atrial fibrillation (AF) significantly increases stroke and systemic embolism risk.
  • The left atrial appendage (LAA) is a primary source of thromboembolism in AF patients.
  • Oral anticoagulation is the standard, but LAA closure (LAAC) is an emerging alternative.

Purpose of the Study:

  • To review the evolving field of Left Atrial Appendage Closure (LAAC).
  • To discuss recent clinical data, ongoing studies, and limitations of LAAC.
  • To highlight LAAC as an alternative or complementary treatment for stroke risk reduction in AF.

Main Methods:

  • Review of moderate-sized randomized clinical studies comparing catheter-based LAAC with vitamin K antagonists.
  • Analysis of data from ongoing randomized clinical trials comparing LAAC with best medical care (including NOACs).
  • Inclusion of findings from the LAAOS III study on surgical LAAC during cardiac surgery.

Main Results:

  • Catheter-based LAAC has demonstrated efficacy and safety, with continuous device and technique improvements.
  • Surgical LAAC in the LAAOS III study reduced stroke risk in AF patients on anticoagulation.
  • Growing evidence supports LAAC, with numerous trials evaluating its effectiveness in various clinical settings.

Conclusions:

  • Left atrial appendage closure is a rapidly advancing therapeutic option for AF-related thromboembolism.
  • Further research and ongoing trials are crucial to define optimal use and compare LAAC with current best practices.
  • LAAC, both percutaneous and surgical, holds significant promise for stroke risk reduction in atrial fibrillation.

Keywords:
Atrial fibrillationLeft atrial appendage closureOral anticoagulationStroke prevention

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K
Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

3.7K

Related Concept Videos

Heart Valves01:16

Heart Valves

The human heart is a complex organ with an intricate system of valves that regulate blood flow. There are two main types of valves: atrioventricular (AV) valves and semilunar valves.
The AV valves prevent the backflow of blood from the ventricles to the atria during ventricular contraction. These valves function with the assistance of the chordae tendineae and papillary muscles. When the ventricles are relaxed, the chordae tendineae are slack, allowing blood to flow from the atria into the...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...